Results 1 to 10 of about 24,779 (184)

Mechanism of calcitriol regulating parathyroid cells in secondary hyperparathyroidism

open access: yesFrontiers in Pharmacology, 2022
A common consequence of chronic renal disease is secondary hyperparathyroidism (SHPT) and is closely related to the mortality and morbidity of uremia patients.
Zeli Xiang   +4 more
doaj   +1 more source

Hypercalciuria and hyperparathyroidism — is there always a connection?

open access: yesОжирение и метаболизм, 2022
Hypercalciuria is a pathological condition characterized by an excess of daily calcium excretion. A high concentration of urine calcium can initiate stone formation. There are several types of hypercalciuria, each requires an individual approach.
S. S. Mirnaya, A. K. Eremkina
doaj   +1 more source

Pathogenesis of secondary hyperparathyroidism [PDF]

open access: yesNephrology Dialysis Transplantation, 1994
The past 20 years has witnessed a dramatic improvement in our understanding of the factors involved in the pathogenesis of secondary hyperparathyroidism in chronic renal insufficiency. The major causes are retention of phosphorus, relatively low levels of serum calcium, and decreased 1,25-(OH)2D3 (calcitriol) levels.
E, Slatopolsky, J A, Delmez
openaire   +4 more sources

Pathogenesis of Secondary Hyperparathyroidism [PDF]

open access: yesThe International Journal of Artificial Organs, 2009
Chronic renal failure is the primary cause of secondary hyperparathyroidism (SHPT). Patients with mineral metabolism disorders commonly present with low serum calcium levels, hyperphosphatemia, and calcitriol deficiency. In normal renal function subjects, parathyroid cells have a low turnover and rarely undergo mitoses.
M.G. Cozzolino   +5 more
openaire   +3 more sources

VITAMIN D DEFICIENCY PANDEMIC, A REALITY OR AN OVER DIAGNOSIS? NEED TO RETHINK VITAMIN D DEFICIENCY CUT OFF LEVELS

open access: yesPakistan Armed Forces Medical Journal, 2020
Objective: To determine clinical decision limits (cut off points) for vitamin D deficiency based on secondary hyperparathyroidism. Study Design: Cross sectional study.
Afshan Bibi   +5 more
doaj   +6 more sources

Secondary Hyperparathyroidism in Osteomalacia [PDF]

open access: yesBMJ, 1970
Twenty-one patients with histologically proved osteomalacia from various causes were investigated for biochemical and radiological evidence of osteomalacia and secondary hyperparathyroidism. Among the 15 who maintained a normal serum calcium, seven had a raised phosphate excretion index, seven had a raised serum alkaline phosphatase, and six had ...
N C, Thalassinos, S, Wicht, G F, Joplin
openaire   +2 more sources

Disputable Issues of Etiology and Pathogenesis of Tertiary Hyperparathyroidism

open access: yesActa Biomedica Scientifica, 2019
Hyperparathyroidism is a clinical and laboratory syndrome characterized by high production of the chief cells of the parathyroid hormone, a calcium-phosphorus metabolism disorder and the organ failure (kidneys, bone tissue).There are primary, secondary ...
G. A. Bersenev   +2 more
doaj   +1 more source

Recent advances in understanding and managing secondary hyperparathyroidism in chronic kidney disease [version 1; peer review: 3 approved]

open access: yesF1000Research, 2020
Secondary hyperparathyroidism is a complex pathology that develops as chronic kidney disease progresses. The retention of phosphorus and the reductions in calcium and vitamin D levels stimulate the synthesis and secretion of parathyroid hormone as well ...
María E. Rodríguez-Ortiz   +1 more
doaj   +1 more source

Brown Tumor of the Cervical Spines: A Case Report with Literature Review [PDF]

open access: yesAsian Spine Journal, 2015
To report a rare case of axis brown tumor and to review literature of cervical spine brown tumor. Brown tumor is a rare bone lesion, incidence less than 5% in primary hyperparathyroidism.
Mohammad Dursi Alfawareh   +3 more
doaj   +1 more source

Surgical Management of Secondary Hyperparathyroidism

open access: yesKidney International Reports, 2021
Secondary hyperparathyroidism (SHPT) affects a majority of patients with chronic kidney disease (CKD) of stage 3 or worse. Despite the development of calcimimetics and their effectiveness in treating SHPT, many patients continue to fail medical ...
Gabrielle K. Steinl, Jennifer H. Kuo
doaj   +1 more source

Home - About - Disclaimer - Privacy